WuXi Biologics (Cayman) Inc. (2269.HK)
2269.HK Stock Price Chart
Explore WuXi Biologics (Cayman) Inc. interactive price chart. Choose custom timeframes to analyze 2269.HK price movements and trends.
2269.HK Company Profile
Discover essential business fundamentals and corporate details for WuXi Biologics (Cayman) Inc. (2269.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Jun 2017
Employees
12.58K
Website
https://www.wuxibiologics.comCEO
Zhisheng Chen
Description
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
2269.HK Financial Timeline
Browse a chronological timeline of WuXi Biologics (Cayman) Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Mar 2026
Earnings released on 19 Aug 2025
EPS came in at $0.60 surpassing the estimated $0.49 by +22.29%, while revenue for the quarter reached $10.92B , beating expectations by +2.01%.
Earnings released on 24 Mar 2025
EPS came in at $0.24 falling short of the estimated $0.47 by -48.87%, while revenue for the quarter reached $10.75B , beating expectations by +4.33%.
Earnings released on 21 Aug 2024
EPS came in at $0.38 falling short of the estimated $0.44 by -14.63%, while revenue for the quarter reached $9.21B , beating expectations by +2.70%.
Earnings released on 27 Mar 2024
EPS came in at $0.29 surpassing the estimated $0.28 by +4.87%, while revenue for the quarter reached $9.45B , missing expectations by -16.76%.
Earnings released on 23 Aug 2023
EPS came in at $0.56 falling short of the estimated $0.59 by -5.05%, while revenue for the quarter reached $9.18B , beating expectations by +4.36%.
Earnings released on 23 Mar 2023
EPS came in at $0.49 surpassing the estimated $0.43 by +14.32%, while revenue for the quarter reached $9.18B , beating expectations by +1.60%.
Earnings released on 17 Aug 2022
EPS came in at $0.68 surpassing the estimated $0.40 by +69.25%, while revenue for the quarter reached $8.44B , missing expectations by -26.54%.
Earnings released on 31 Dec 2021
EPS came in at $0.43 falling short of the estimated $0.43 by -0.65%, while revenue for the quarter reached $7.20B , beating expectations by +5.65%.
Earnings released on 23 Aug 2021
EPS came in at $0.50 surpassing the estimated $0.49 by +1.87%, while revenue for the quarter reached $5.29B , beating expectations by +18.26%.
Earnings released on 23 Mar 2021
EPS came in at $0.26 falling short of the estimated $0.27 by -2.90%, while revenue for the quarter reached $4.36B , beating expectations by +4.12%.
Stock split effective on 30 Nov 2020
Shares were split 3 : 1 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 16 Nov 2020
Shares were split 3 : 1 , changing the number of shares outstanding and the price per share accordingly.
2269.HK Stock Performance
Access detailed 2269.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.